paclitaxel has been researched along with Cystadenocarcinoma, Papillary in 48 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 15 (31.25) | 18.2507 |
2000's | 25 (52.08) | 29.6817 |
2010's | 7 (14.58) | 24.3611 |
2020's | 1 (2.08) | 2.80 |
Authors | Studies |
---|---|
Batman, S; Bohn, J; Bruegl, A; Caughey, A; Hersh, A; Weisenberger, MW; Winter, W | 1 |
Broadwater, G; Chino, JP; Foote, J; Gaillard, S; Havrilesky, LJ; Hong, JC | 1 |
Devi, S; Fatima, R; Jagadish, N; Kumar, V; Sharma, A; Suri, A; Suri, V | 1 |
An, N; Gao, M; Gao, YN; Jiang, GQ; Yan, X | 1 |
Antsaklis, A; Haidopoulos, D; Papoutsis, D; Rodolakis, A; Sotiropoulou, M | 1 |
Bolz, K; Cheuk, R; Goh, J; Janda, M; Kondalsamy-Chennakesavan, S; Mileshkin, L; Nicklin, JL; Obermair, A; Perrin, LC; Sykes, P; Vasey, P; Wyld, D | 1 |
Döger, FK; Küçük, M; Riza Obadaşi, A; Sezer, SD; Yüksel, H | 1 |
Berman, ML; Dalmar, A; Lentz, SE; Mahdavi, A; Tajalli, TR; Vasilev, SA | 1 |
Abu-Rustum, NR; Aghajanian, C; Alektiar, KM; Barakat, RR; Damast, S; Gardner, GJ; Kiess, AP; Kollmeier, MA; Makker, V | 1 |
Cosio, S; Fuso, L; Gadducci, A; Landoni, F; Maggino, T; Sartori, E; Zola, P | 1 |
Matsui, H; Nagai, Y; Seki, K; Sekiya, S; Suzuka, K; Tanaka, N | 1 |
Calderisi, MD; Corona, F; De Petris, L; Di Placido, M; Longo, F; Malizia, A; Marenga, G; Mongardini, M; Patrizi, V; Priore, FM; Schillaci, F; Scirocchi, R; Stagnitti, F; Tiberi, R | 1 |
Anderson, P; Fields, A; Goldberg, G; Guha, C; Gupta, S; Jones, J; Khabele, D; Runowicz, C; Sood, BM; Vikram, B | 1 |
Abraham, R; Cronk, M; Perrin, L | 1 |
Asmar, L; Bailey, CL; Gordon, AN; Messing, MJ; Pippitt, CH; Savage, J; Street, DG; Young, JA | 1 |
Camatte, S; Castaigne, D; Dubernard, G; Duvillard, P; Fourchotte, V; Lhommé, C; Morice, P; Pautier, P; Pomel, C; Rey, A; Thoury, A | 1 |
Gao, YN; Li, WF; Liu, JX; Tang, WS; Wang, W | 1 |
Berman, ML; Chan, JK; Hamilton, CA; Husain, A; Kapp, DS; Liou, WS; Osann, K; Teng, NN | 1 |
Gross, C; Krüger, U; Rompel, R; Scholz, S | 1 |
Horowitz, NS; Krasner, CN; Lee, SI; Oliva, E; Roche, M; Supko, JG | 1 |
Bădulescu, A; Bădulescu, F; Popescu, CF; Schenker, M; Stoica, Z | 1 |
Carrucciu, GM; Gramignano, G; Mais, V; Mantovani, G; Melis, GB; Parodo, G | 1 |
Wang, HJ; Zheng, WX | 1 |
Einstein, MH; Fields, AL; Gebb, J; Goldberg, GL; Novetsky, AP | 1 |
Abacioglu, U; Abdah-Bortnyak, R; Amit, A; Atahan, IL; Azria, D; Gold, DG; Goldberg, H; Kuten, A; Lavie, O; Meirovitz, A; Miller, RC; Ozsahin, M; Poortmans, PM; Steiner, M; Villà, S; Yildiz, F; Zidan, J | 1 |
Furukawa, N; Haruta, S; Kanayama, S; Kawaguchi, R; Kitanaka, T; Kobayashi, H; Naruse, K; Oi, H; Sado, T; Sakata, M; Yamada, Y; Yoshida, S | 1 |
Abushahin, F; Belinson, J; Fader, AN; Gibbons, H; Markman, M; Rose, P; Starks, D; von Gruenigen, V | 1 |
Fang, SH; Gao, YL; Yu, AJ | 1 |
Donner, LR; Kavanagh, JJ; Kudelka, AP; Mante, R; Silva, E; Wilailak, S | 1 |
Jenkins, JJ; Mandrell, BN; Pratt, CB; Smiley, LM; Wall, JE | 1 |
Resnik, E; Taxy, JB | 1 |
Balat, O; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Tunca, JC; Verschraegen, C | 1 |
Goldberg, JM; Hempling, RE; Piver, MS; Recio, FO | 1 |
Fennelly, D; Gogas, H | 1 |
Aghajanian, C; Fennelly, D; McKenzie, M; Norton, L; O'Connor, C; O'Flaherty, C; Shapiro, F; Spriggs, D; Tong, W | 1 |
Edwards, CL; Herrada, J; Kavanagh, JJ; Kudelka, AP; Shin, DM; Tornos, C; Verschraegen, CF | 1 |
Belinson, J; Hurteau, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Sutton, G; Webster, K | 1 |
Belinson, JL; Kennedy, AW; Kulp, B; Markman, M; Peterson, G; Rybicki, LA; Webster, KD | 1 |
Benjapibal, M; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Vadhan-Raj, S; Valero, V; Vasuratna, A; Verschraegen, CF | 1 |
Cohen, Y; Horowitz, J; Meirovitz, M; Piura, B | 1 |
DiSaia, PJ; Le, TD; Rutgers, JL; Yamada, SD | 1 |
Belinson, JL; Kennedy, AW; Markman, M; Webster, KD; Zanotti, KM | 1 |
Eltabbakh, GH; Garafano, LL; Hammond, JM; Moody, J | 1 |
Markman, M | 1 |
Aoki, Y; Kazama, JJ; Kurata, H; Tanaka, K; Tomita, M | 1 |
Bevers, M; Bodurka-Bevers, D; Burke, TW; Gershenson, DM; Levenback, C; Ramondetta, L | 1 |
Kairi-Vasilatou, E; Koutselini, HA; Lazaris, AC; Papayannopoulou, A; Thomopoulou, G | 1 |
Fujiyoshi, K; Harada, C; Ishimatsu, J; Kamura, T; Kawagoe, H; Kawata, T; Nishio, S; Sugiyama, T; Tsunawaki, A | 1 |
3 review(s) available for paclitaxel and Cystadenocarcinoma, Papillary
Article | Year |
---|---|
Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review.
Topics: Adult; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Papillary; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, First | 2007 |
[Precursor lesions of type II endometrial cancer: diagnostic criteria and pathogenesis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma in Situ; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease Progression; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hysterectomy; Paclitaxel; Precancerous Conditions; Radiotherapy, Adjuvant; Uterine Neoplasms | 2007 |
Avascular necrosis following extensive chemotherapy and dexamethasone treatment in a patient with advanced ovarian cancer: case report and review of the literature.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Papillary; Dexamethasone; Etoposide; Female; Humans; Middle Aged; Neoplasm, Residual; Osteonecrosis; Ovarian Neoplasms; Paclitaxel | 1996 |
6 trial(s) available for paclitaxel and Cystadenocarcinoma, Papillary
Article | Year |
---|---|
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Paclitaxel; Prospective Studies; Quality of Life; Survival Analysis; Uterine Neoplasms | 2011 |
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2004 |
Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Prospective Studies; Uterine Neoplasms | 2008 |
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 1997 |
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 1998 |
Treatment of uterine papillary serous carcinoma with paclitaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Papillary; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Uterine Neoplasms | 2001 |
39 other study(ies) available for paclitaxel and Cystadenocarcinoma, Papillary
Article | Year |
---|---|
Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Markov Chains; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Quality-Adjusted Life Years; Receptor, ErbB-2; Trastuzumab; United States; Uterine Neoplasms | 2021 |
Impact of Chemotherapy and Radiotherapy on Management of Early Stage Clear Cell and Papillary Serous Carcinoma of the Uterus.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Hysterectomy; Lymph Node Excision; Middle Aged; Neoplasm Staging; Paclitaxel; United States; Uterine Neoplasms | 2017 |
Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Papillary; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Injections, Intralesional; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; RNA Interference; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2018 |
[Impact of neoadjuvant chemotherapy on the survival of patients with stage IIIc and IV epithelial ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Rate; Taxoids | 2008 |
Peritoneal implantations of papillary serous ovarian cystadenocarcinoma 13 days after initial laparoscopic treatment for a presumed benign ovarian cyst.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Frozen Sections; Humans; Laparoscopy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Young Adult | 2009 |
Papillary serous adenocarcinoma of the uterine cervix: a case report.
Topics: Aged; Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Fatal Outcome; Female; Humans; Hysterectomy; Paclitaxel; Uterine Cervical Neoplasms | 2011 |
Role of adjuvant chemotherapy in patients with early stage uterine papillary serous cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; California; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Neoplasms | 2011 |
Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Drug Administration Schedule; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel; Retrospective Studies; Salpingectomy; Survival Analysis; Treatment Outcome | 2012 |
Analysis of treatment failures and survival of patients with uterine papillary serous carcinoma: a Cooperation Task Force (CTF) Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Postoperative Complications; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Failure; Uterine Neoplasms; Young Adult | 2012 |
Impact of maintenance chemotherapy on disease-free survival in patients with stage Ic and II epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Ifosfamide; Japan; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2002 |
[Peritoneal papillary serous carcinoma: clinical report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Papillary; Fatal Outcome; Female; Humans; Paclitaxel; Peritoneal Neoplasms | 2002 |
Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Shiga Toxins; Survival Analysis; Treatment Failure; Uterine Neoplasms | 2003 |
Case report of a generalized seizure related to Paclitaxel infusion.
Topics: Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Papillary; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Seizures | 2004 |
Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2004 |
[Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids | 2005 |
Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Doxorubicin; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Regression Analysis; Survival Rate | 2005 |
[Erosive verrucous skin lesion on the umbilicus of a 83 year old woman].
Topics: Adnexa Uteri; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Hysterectomy; Immunohistochemistry; Lymph Node Excision; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Skin; Skin Neoplasms; Time Factors; Umbilicus | 2005 |
Case records of the Massachusetts General Hospital. Case 11-2006. A 54-year-old woman with a mass in the pelvis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Diagnosis, Differential; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed | 2006 |
The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Topics: CA-125 Antigen; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan; Treatment Outcome | 2005 |
Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Uterine Neoplasms | 2008 |
Peritoneal disseminated recurrence and lung metastasis after surgery for stage IA uterine papillary serous carcinoma of the endometrium: a case report.
Topics: Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 2008 |
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome | 2008 |
[Analysis of therapeutic result and prognostic factor in primary fallopian tube carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Papillary; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Hysterectomy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Ovariectomy; Paclitaxel; Survival Rate; Taxoids | 2007 |
Peritoneal papillary serous carcinoma: response to Taxol in platinum resistant disease.
Topics: Carboplatin; Cystadenocarcinoma, Papillary; Drug Resistance; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 1995 |
Effectiveness of paclitaxel in treating papillary serous carcinoma of the peritoneum in an adolescent.
Topics: Adolescent; Cystadenocarcinoma, Papillary; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Remission Induction | 1995 |
Neoadjuvant chemotherapy in uterine papillary serous carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Female; Humans; Paclitaxel; Uterine Neoplasms | 1996 |
Prolonged stabilization of progressive platinum-refractory ovarian cancer with paclitaxel: brief report.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Quality of Life; Salvage Therapy; Treatment Failure | 1996 |
Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cisplatin; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 1996 |
Remission with carboplatin of paclitaxel resistant primary peritoneal papillary serous carcinoma: case report.
Topics: Aged; Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Papillary; Drug Resistance; Female; Humans; Paclitaxel; Peritoneal Neoplasms | 1997 |
Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 1998 |
Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma; Cyclophosphamide; Cystadenocarcinoma, Papillary; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |
Dermatomyositis and peritoneal papillary serous carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Ascites; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Dermatomyositis; Female; Humans; Hysterectomy; Laparoscopy; Laparotomy; Mucin-1; Paclitaxel; Peritoneal Neoplasms; Pleural Effusion | 1999 |
Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Papillary; Female; Humans; Neoplasm Staging; Paclitaxel; Remission Induction; Uterine Neoplasms | 1999 |
The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Survival Rate; Uterine Neoplasms | 1999 |
The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Papillary; Endometrial Neoplasms; Female; Humans; Megestrol Acetate; Paclitaxel; Prognosis; Treatment Outcome | 1999 |
Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Disease-Free Survival; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests | 2001 |
Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cystadenocarcinoma, Papillary; Female; Humans; Kidney Failure, Chronic; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Renal Dialysis; Thrombocytopenia | 2001 |
Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleus; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Diagnosis, Differential; Female; Humans; Mesothelioma; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2001 |
[A case of extraovarian primary peritoneal carcinoma successfully treated with weekly paclitaxel].
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents, Phytogenic; Cisplatin; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Paclitaxel; Peritoneal Neoplasms | 2002 |